Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

Conclusions Candesartan and Amlodipine equally reduce the number of CV events in high-risk hypertensive patients under strict BP control. Candesartan is more beneficial than Amlodipine p for hypertensive patients with chronic kidney disease or obesity, and may be preferable for patients with metabolic syndrome.
Randomized Trial of ARB based versus NonARB Standard Therapy in Patients with CAD and and Hypertension The Heart Institute of Japan Candesartan RRandomized d i d ttrial i l ffor EEvaluation l ti iin Coronary Artery Disease (HIJCREATE) Presented at 2007 AHA
Page 1 and 2: Comparison of Candesartan vs Amlodi
Page 3 and 4: 30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 5 and 6: LIFE Incidence of Diabetes Mellitus
Page 7 and 8: m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10: ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 20 and 21: Dosage Schedule Schedule 1 month BP
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 28 and 29: Comparison of Cardiovascular Cardio
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 38 and 39: BP reduction during studies mmHg SB
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 50 and 51: Endpoint Primary Endpoint Major Adv
Page 52 and 53: Patient Characteristics (1) Candesa
Page 54 and 55: Medications at at Randomization Ran
Page 56 and 57: Primary Primary Endpoint Cumulative
Page 58 and 59: Candesartan vs vs Standard Standard
Page 60 and 61: Subgroup Subgroup analysis analysis
Page 62 and 63: Summary IIn comparison i with i h s
Page 64: Conclusions Candesartan and Amlodip
Page 68 and 69: % Isolated systolic hypertension 0
Page 70: Predictors of new-onset atrial fibr

Comparison of Candesartan vs Amlodipine Comparison of ...

Create successful ePaper yourself

Delete template?

Save as template?